v3.26.1
Consolidated Statements of Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Net sales $ 1,428,731 $ 1,076,881
Cost of goods sold [1] 927,765 920,582
Gross profit 500,966 156,299
Selling, general and administrative expenses 137,406 123,502
Restructuring charges and asset write-offs 25,866 (1,063)
Research and development expenses 9,170 14,099
Loss on sale of business 95,018 0
Operating profit 233,506 19,761
Interest and financing expenses (33,121) (48,977)
Other income, net 53,810 10,250
Income (loss) before income taxes and equity in net income of unconsolidated investments 254,195 (18,966)
Income tax expense (benefit) 21,511 (3,978)
Income (loss) before equity in net income of unconsolidated investments 232,684 (14,988)
Equity in net income of unconsolidated investments (net of tax) 96,293 64,286
Net income 328,977 49,298
Net income attributable to noncontrolling interests (9,886) (7,950)
Net income attributable to Albemarle Corporation 319,091 41,348
Mandatory convertible preferred stock dividends (41,688) (41,688)
Net income (loss) attributable to Albemarle Corporation common shareholders $ 277,403 $ (340)
Basic earnings (loss) per share attributable to common shareholders (in dollars per share) $ 2.35 $ 0.00
Diluted earnings (loss) per share attributable to common shareholders (in dollars per share) $ 2.34 $ 0.00
Weighted-average common shares outstanding - basic (in shares) 117,854 117,603
Weighted-average common shares outstanding - diluted (in shares) 118,607 117,603
[1] Included purchases from related unconsolidated affiliates of $128.2 million and $119.8 million for the three-month periods ended March 31, 2026 and 2025, respectively.